XML 31 R20.htm IDEA: XBRL DOCUMENT v3.20.2

Revenues (Tables)

9 Months Ended

Sep. 30, 2020

Segment Reporting [Abstract]

Summary of net revenue

The Company’s net revenues consisted of the following for the three and nine months ended September 30, 2020 and 2019:

			Three months ended September 30,												Nine months ended September 30,
			2020						2019						2020						2019
Products:
Acetadote			$	218,462					$	777,185					$	1,527,173					$	2,608,160
Omeclamox-Pak			516,066						116,063						640,435						794,205
Kristalose			3,615,557						2,924,237						10,387,046						9,720,434
Vaprisol			406,162						224,940						790,817						724,143
Caldolor			1,416,146						1,170,567						3,677,434						3,543,166
Vibativ			2,813,249						1,451,595						8,551,125						6,156,653
Other revenue			265,047						270,852						1,605,570						1,535,981
Total net revenues			$	9,250,689					$	6,935,439					$	27,179,600					$	25,082,742

X

- Definition

Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

+ Details

Name:	us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration